Can-Fite BioPharma Ltd. (CANF)Healthcare | Biotechnology | Ramat Gan, Israel | NYSE American
3.04 USD
-0.04
(-1.299%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.04 Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:07 p.m. EDT
CANF is currently in a highly volatile and negative trend, with a significant decline in price over the past few months. The recent price history shows a consistent downward movement, with the current price hovering near its 52-week low. The negative earnings and poor financial metrics, such as negative forward PE and operating margins, indicate weak fundamentals. The stock's low volume and short interest suggest limited liquidity and potential short-term pressure. While there are some positive news headlines, the overall sentiment is bearish. For short-term traders, the stock may offer a buy-the-dip opportunity, but the low momentum and high volatility make it a risky proposition. Long-term investors should be cautious due to the lack of sustainable growth and poor financial health. The absence of dividends further reduces its appeal for income-focused investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.171531 |
| MSTL | 0.184935 |
| AutoETS | 0.192994 |
| AutoARIMA | 0.192996 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.37 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.003 |
| Excess Kurtosis | 1.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.27 |
| Revenue per Share | 0.492 |
| Market Cap | 7,133,831 |
| Forward P/E | -4.16 |
| Beta | -0.10 |
| Website | https://www.canfite.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.87741935 |
| Address1 | 26 Ben Gurion Street |
| All Time High | 28,380.0 |
| All Time Low | 2.9 |
| Ask | 3.23 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 28,260 |
| Average Daily Volume3 Month | 694,554 |
| Average Volume | 694,554 |
| Average Volume10Days | 28,260 |
| Beta | -0.101 |
| Bid | 3.02 |
| Bid Size | 100 |
| Book Value | 4.272 |
| City | Ramat Gan |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.04 |
| Current Ratio | 3.457 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.1599 |
| Day Low | 2.9399 |
| Debt To Equity | 1.27 |
| Display Name | Can-Fite BioPharma |
| Dividend Date | 1,557,446,400 |
| Earnings Timestamp End | 1,756,728,000 |
| Earnings Timestamp Start | 1,756,378,740 |
| Ebitda | -9,926,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.459 |
| Enterprise To Revenue | 11.254 |
| Enterprise Value | 4,557,682 |
| Eps Forward | -0.73 |
| Eps Trailing Twelve Months | -10.75 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 3 924 9378 |
| Fifty Day Average | 3.8292 |
| Fifty Day Average Change | -0.78920007 |
| Fifty Day Average Change Percent | -0.20610051 |
| Fifty Two Week Change Percent | -87.741936 |
| Fifty Two Week High | 25.0 |
| Fifty Two Week High Change | -21.96 |
| Fifty Two Week High Change Percent | -0.87839997 |
| Fifty Two Week Low | 2.9 |
| Fifty Two Week Low Change | 0.13999987 |
| Fifty Two Week Low Change Percent | 0.048275813 |
| Fifty Two Week Range | 2.9 - 25.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,212,200,000 |
| Float Shares | 4,284,879 |
| Forward Eps | -0.73 |
| Forward P E | -4.1643834 |
| Free Cashflow | -4,985,750 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 405,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.01485 |
| Implied Shares Outstanding | 2,346,655 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,767,571,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel. |
| Long Name | Can-Fite BioPharma Ltd. |
| Market | us_market |
| Market Cap | 7,133,831 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_676937 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -9,828,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 6,849,620 |
| Number Of Analyst Opinions | 1 |
| Open | 3.1 |
| Operating Cashflow | -8,949,000 |
| Operating Margins | -24.8867 |
| Payout Ratio | 0.0 |
| Phone | 972 3 924 1114 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.04 |
| Post Market Time | 1,776,463,371 |
| Previous Close | 3.08 |
| Price Hint | 4 |
| Price To Book | 0.7116105 |
| Price To Sales Trailing12 Months | 17.614397 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.127 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -1.2987 |
| Regular Market Day High | 3.1599 |
| Regular Market Day Low | 2.9399 |
| Regular Market Day Range | 2.9399 - 3.1599 |
| Regular Market Open | 3.1 |
| Regular Market Previous Close | 3.08 |
| Regular Market Price | 3.04 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 31,405 |
| Return On Assets | -0.66746 |
| Return On Equity | -1.78237 |
| Revenue Growth | -0.433 |
| Revenue Per Share | 0.492 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,142,547 |
| Shares Percent Shares Out | 0.0175 |
| Shares Short | 37,433 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 85,759 |
| Short Name | Can-Fite Biopharma Ltd |
| Short Percent Of Float | 0.0176 |
| Short Ratio | 0.02 |
| Source Interval | 15 |
| Symbol | CANF |
| Target High Price | 50.0 |
| Target Low Price | 50.0 |
| Target Mean Price | 50.0 |
| Target Median Price | 50.0 |
| Total Cash | 8,540,000 |
| Total Cash Per Share | 1.993 |
| Total Debt | 71,000 |
| Total Revenue | 405,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -10.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.72885 |
| Two Hundred Day Average Change | -5.6888504 |
| Two Hundred Day Average Change Percent | -0.65172964 |
| Type Disp | Equity |
| Volume | 31,405 |
| Website | https://www.canfite.com |
| Zip | 5,257,346 |